Chuck Royce's MYGN Position Overview
Chuck Royce (via Royce & Associates Lp) currently holds 605,000 shares of Myriad Genetics, Inc. (MYGN) worth $3.72 M, representing 0.04% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 30 quarters.
Based on 13F filings, Chuck Royce has maintained a strategic position in MYGN, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 670,000 shares. Largest reduction occurred in Q4 2014, reducing 3.82 M shares.
Analysis based on 13F filings available since 2013 Q2
Chuck Royce's Myriad Genetics (MYGN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Myriad Genetics (MYGN) Trades by Chuck Royce
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -65,000 | Reduce 9.70% | 605,000 | $6.15 |
| Q3 2025 | +670,000 | New Buy | 670,000 | $7.23 |
| Q3 2020 | -3,157 | Sold Out | 0 | $0.00 |
| Q2 2020 | +287 | Add 10.00% | 3,157 | $11.40 |
| Q1 2020 | +796 | Add 38.38% | 2,870 | $14.29 |
| Q4 2019 | -191,088 | Reduce 98.93% | 2,074 | $27.00 |
| Q3 2019 | +15,664 | Add 8.82% | 193,162 | $28.63 |
| Q2 2019 | +35,267 | Add 24.80% | 177,498 | $27.78 |
| Q1 2019 | +131,246 | Add 1194.77% | 142,231 | $33.20 |
| Q4 2018 | -56,788 | Reduce 83.79% | 10,985 | $29.04 |
| Q3 2018 | +225 | Add 0.33% | 67,773 | $46.01 |
| Q2 2018 | +116 | Add 0.17% | 67,548 | $37.37 |
| Q1 2018 | +40,043 | Add 146.20% | 67,432 | $29.56 |
| Q4 2017 | +34 | Add 0.12% | 27,389 | $34.36 |
| Q3 2017 | +27,355 | New Buy | 27,355 | $36.19 |
| Q4 2016 | -90,369 | Sold Out | 0 | $0.00 |
| Q3 2016 | -847,129 | Reduce 90.36% | 90,369 | $20.58 |
| Q2 2016 | -347,200 | Reduce 27.03% | 937,498 | $30.60 |
| Q1 2016 | -130,200 | Reduce 9.20% | 1.28 M | $37.43 |
| Q4 2015 | -856,770 | Reduce 37.72% | 1.41 M | $43.16 |
| Q3 2015 | -551,535 | Reduce 19.54% | 2.27 M | $37.48 |
| Q2 2015 | -580,997 | Reduce 17.07% | 2.82 M | $33.99 |
| Q1 2015 | -1.68 M | Reduce 33.05% | 3.4 M | $35.40 |
| Q4 2014 | -3.82 M | Reduce 42.91% | 5.08 M | $34.06 |
| Q3 2014 | -393,413 | Reduce 4.23% | 8.91 M | $38.57 |
| Q2 2014 | -136,235 | Reduce 1.44% | 9.3 M | $38.92 |
| Q1 2014 | -1.41 M | Reduce 12.98% | 9.44 M | $34.19 |
| Q4 2013 | -163,500 | Reduce 1.49% | 10.84 M | $20.98 |
| Q3 2013 | +262,180 | Add 2.44% | 11.01 M | $23.50 |
| Q2 2013 | +10.74 M | Add 0.00% | 10.74 M | $26.87 |
Chuck Royce's Myriad Genetics Investment FAQs
Chuck Royce first purchased Myriad Genetics, Inc. (MYGN) in Q2 2013, acquiring 10,744,395 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Chuck Royce has held Myriad Genetics, Inc. (MYGN) for 30 quarters since Q2 2013.
Chuck Royce's largest addition to Myriad Genetics, Inc. (MYGN) was in Q2 2013, adding 10,744,395 shares worth $288.7 M.
According to the latest 13F filing for Q4 2025, Chuck Royce's firm, Royce & Associates Lp, owns 605,000 shares of Myriad Genetics, Inc. (MYGN), valued at approximately $3.72 M.
As of the Q4 2025 filing, Myriad Genetics, Inc. (MYGN) represents approximately 0.04% of Chuck Royce's publicly disclosed stock portfolio, making it one of their key holdings.
Chuck Royce's peak holding in Myriad Genetics, Inc. (MYGN) was 11,006,575 shares, as reported at the end of Q3 2013.